A detailed history of Candriam S.C.A. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Candriam S.C.A. holds 327,402 shares of BMRN stock, worth $21.5 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
327,402
Previous 525,138 37.65%
Holding current value
$21.5 Million
Previous $43.2 Million 46.77%
% of portfolio
0.13%
Previous 0.27%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $13.6 Million - $18.6 Million
-197,736 Reduced 37.65%
327,402 $23 Million
Q2 2024

Aug 05, 2024

BUY
$74.43 - $92.22 $10.9 Million - $13.5 Million
146,827 Added 38.81%
525,138 $43.2 Million
Q1 2024

May 03, 2024

BUY
$83.81 - $99.0 $7.66 Million - $9.05 Million
91,383 Added 31.85%
378,311 $33 Million
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $4.7 Million - $6.07 Million
-61,621 Reduced 17.68%
286,928 $27.7 Million
Q3 2023

Nov 13, 2023

SELL
$85.07 - $94.48 $5.91 Million - $6.56 Million
-69,478 Reduced 16.62%
348,549 $30.8 Million
Q2 2023

Aug 08, 2023

SELL
$86.68 - $100.3 $11.9 Million - $13.8 Million
-137,428 Reduced 24.74%
418,027 $36.2 Million
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $4.75 Million - $6.35 Million
54,144 Added 10.8%
555,455 $54 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $13.6 Million - $18.3 Million
168,416 Added 50.59%
501,311 $51.9 Million
Q3 2022

Nov 10, 2022

SELL
$82.16 - $96.94 $4.83 Million - $5.69 Million
-58,735 Reduced 15.0%
332,895 $28.2 Million
Q2 2022

Aug 03, 2022

SELL
$71.48 - $86.85 $1.55 Million - $1.88 Million
-21,647 Reduced 5.24%
391,630 $32.5 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $10.3 Million - $12.9 Million
139,070 Added 50.72%
413,277 $31.9 Million
Q4 2021

Feb 10, 2022

SELL
$71.72 - $91.47 $143,440 - $182,940
-2,000 Reduced 0.72%
274,207 $24.2 Million
Q3 2021

Nov 09, 2021

BUY
$74.77 - $85.47 $12.6 Million - $14.4 Million
168,364 Added 156.12%
276,207 $21.3 Million
Q2 2021

Jul 20, 2021

SELL
$75.51 - $84.79 $18.9 Million - $21.2 Million
-250,187 Reduced 69.88%
107,843 $9 Million
Q4 2020

Jan 22, 2021

SELL
$72.61 - $90.2 $710,779 - $882,967
-9,789 Reduced 2.66%
358,030 $31.4 Million
Q3 2020

Oct 19, 2020

SELL
$71.87 - $131.03 $130,875 - $238,605
-1,821 Reduced 0.49%
367,819 $28 Million
Q2 2020

Jul 23, 2020

BUY
$79.55 - $124.22 $3.76 Million - $5.87 Million
47,225 Added 14.65%
369,640 $45.6 Million
Q4 2019

Jan 21, 2020

SELL
$64.27 - $86.37 $2.38 Million - $3.2 Million
-37,105 Reduced 10.32%
322,415 $27,000
Q3 2019

Oct 21, 2019

SELL
$67.4 - $85.11 $5.82 Million - $7.35 Million
-86,410 Reduced 19.38%
359,520 $24,000
Q2 2019

Aug 01, 2019

SELL
$80.35 - $93.9 $1.12 Million - $1.31 Million
-13,922 Reduced 3.03%
445,930 $38 Million
Q4 2018

Feb 14, 2019

BUY
$80.14 - $106.07 $4.48 Million - $5.92 Million
55,859 Added 13.83%
459,852 $39.2 Million
Q3 2018

Nov 07, 2018

BUY
$93.92 - $105.72 $13 Million - $14.7 Million
138,700 Added 52.28%
403,993 $39.2 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $4.22 Million - $5.5 Million
55,500 Added 26.45%
265,293 $25 Million
Q4 2017

Feb 07, 2018

SELL
$80.76 - $95.13 $1.88 Million - $2.21 Million
-23,244 Reduced 9.97%
209,793 $18.7 Million
Q3 2017

Nov 03, 2017

BUY
$80.6 - $94.95 $18.8 Million - $22.1 Million
233,037
233,037 $21.7 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.